Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Rating of "Buy" by Analysts

Key Points

• Lucid Diagnostics Inc. (NASDAQ:LUCD) has received a consensus rating of "Buy" from five brokerages, with an average 12-month price target of $3.55.
• Several institutional investors have recently increased their stakes in Lucid Diagnostics, collectively owning 74.01% of the company’s stock.
• The stock has traded between a 1-year low of $0.72 and a 1-year high of $1.80, currently opening at $1.02.

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have been given an average rating of "Buy" by the five brokerages that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.55.

Several research firms recently commented on LUCD. Ascendiant Capital Markets boosted their price target on Lucid Diagnostics from $7.50 to $7.75 and gave the stock a "buy" rating in a research note on Friday, June 6th. Needham & Company LLC reiterated a "buy" rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research note on Wednesday, July 16th. Wall Street Zen cut Lucid Diagnostics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $2.00 price target on shares of Lucid Diagnostics in a research note on Thursday, May 15th.

Institutional Trading of Lucid Diagnostics

Several institutional investors and hedge funds have recently bought and sold shares of LUCD. Berkshire Asset Management LLC PA acquired a new stake in Lucid Diagnostics during the first quarter valued at approximately $30,000. Traphagen Investment Advisors LLC acquired a new stake in Lucid Diagnostics during the second quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Lucid Diagnostics during the first quarter valued at approximately $37,000. Cubist Systematic Strategies LLC acquired a new stake in Lucid Diagnostics during the first quarter valued at approximately $39,000. Finally, LPL Financial LLC raised its stake in Lucid Diagnostics by 29.1% during the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company's stock valued at $44,000 after buying an additional 12,035 shares in the last quarter. Institutional investors and hedge funds own 74.01% of the company's stock.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD opened at $1.02 on Tuesday. Lucid Diagnostics has a 1-year low of $0.72 and a 1-year high of $1.80. The business has a 50-day moving average of $1.19 and a 200-day moving average of $1.26. The company has a market capitalization of $110.35 million, a price-to-earnings ratio of -0.76 and a beta of 1.21.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.